Skip to main content

Acorda stock plummets 31% on ‘surprising, puzzling, disconcerting’ FDA drug decision

A refusal to file letter means that the company’s drug application wasn’t complete enough and is considered embarrassing for a drug company.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.